Post-earnings recap
Reported
Mon, Nov 9, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
PTC Therapeutics reported a loss that was slightly worse than expected, leading to a 2.24% decline in stock price. The lack of revenue figures and guidance adds to investor uncertainty. Overall, the company faces challenges in improving its financial outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.27 | N/A | -12.99% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance. They did not provide any forward guidance, indicating uncertainty in future results.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.